Clinical Data Amgen scores with new thyroid eye disease formulation PharmaphorumCan Amgen's subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?Clinical DataOphthalmologyRead full story pharminent April 7, 2026 (Last updated: April 8, 2026) Pharmaphorum Can Amgen’s subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster? Clinical DataOphthalmologyRead full story Post navigation Previous: FDA floats new clinical trial reforms; Takeda punts Denali brain drugNext: Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3 Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
